TG Therapeutics, Inc. Announces Double & Triple Combination

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting

Combination of TG-1101, TGR-1202 and bendamustine resulted in 71% ORR, including 43% complete response rate, in relapsed or refractory DLBCL

TGR-1202 continues to demonstrate a favorable and differentiated safety profile when combined with a variety of agents

SAN DIEGO, Dec. 06, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), announced the presentation yesterday of data from three combination studies involving the Company’s lead compounds, TGR-1202, the Company’s once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody at the 58 th American Society of Hematology (ASH) Annual Meeting, in San Diego, California. Michael S. Weiss, the Company’s Executive Chairman and Interim CEO stated, “We are very pleased to continue to see a highly differentiated safety profile for TGR-1202 across multiple double and triple combination studies with a high level of activity.  Each of the four clinical studies presented at the ASH meeting, enhanced our overall understanding of the breadth of activity of TGR-1202.  In addition to DLBCL, FL and CLL, where we have already shown data previously, it was nice to see the flexibility of TGR-1202 and its ability to be combined with brentuximab vedotin in relapsed or refractory Hodgkin’s and with ruxolitinib in Myelofibrosis.” Mr. Weiss continued, “We are also encouraged by the triple combination data of TG-1101, TGR-1202, and bendamustine in relapsed or refractory, difficult to treat, DLBCL and FL patients which showed no discontinuations for a treatment related adverse event, as well as an 80% overall response rate across both DLBCL and FL patients and a high level of CR’s.  We, and our investigators, believe this triplet combination is a promising regimen and plan to study it in this patient population in a registration-directed trial.”

Highlights from yesterday’s presentations include the following:

Poster Presentation: Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma (Abstract Number 4197)

This poster presentation includes data from patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) treated with the triple combination of TG-1101 (ublituximab), TGR-1202 and bendamustine.  Nineteen patients were evaluable for safety of which 15 were evaluable for efficacy (3 patients were too early to evaluate and 1 patient had a non-related adverse event (AE) prior to efficacy assessment). The triple combination appears well tolerated with no discontinuations for a treatment related AE. Neutropenia and anemia were the only Grade 3/4 AE’s occurring in more than 1 patient.  Importantly, no Grade 3/4 transaminitis was reported, no events of pneumonia or pneumonitis, and only 1 transient event of Grade 3 diarrhea, with a duration of 1 day, was observed.  Eleven patients (58%) were refractory to prior treatment.  Median time on study at the data cut off was approximately 6 months with the majority of patients continuing on study and follow-up ongoing.

Efficacy highlights from this poster include:

  • 71% (5 of 7) Overall Response Rate (ORR), including a 43% Complete Response (CR) rate observed in patients with relapsed or refractory DLBCL
  • 88% (7 of 8) ORR, including a 37% CR rate observed in patients with relapsed or refractory FL 4/6 CR’s that were achieved between the DLBCL and FL groups occurred at the first 8 week efficacy assessment
  • First response assessment occurred at Month 3 following initiation of therapy, with durable responses observed notably amongst DLBCL patients.

Poster Presentation: A Phase I Trial of TGR-1202, a Next Generation Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma (Abstract Number 4146)

This poster presentation includes data from patients with relapsed and refractory Hodgkin’s Lymphoma (HL) treated with TGR-1202 at either 400mg or 600mg dosed orally once daily in combination with brentuximab vedotin in continuous 21 day cycles.  14 patients were evaluable for safety, of which 11 were evaluable for efficacy (3 discontinued prior to disease evaluation (2 AE’s and 1 withdrew consent)).  43% (6 of 14) of patients had prior exposure to brentuximab vedotin and all were refractory to prior brentuximab vedotin therapy.  The combination demonstrated tolerability with nausea, diarrhea, and neutropenia being the most prevalent adverse events.  Notably all but one case of diarrhea was Grade 1 or 2 in severity. 

Efficacy highlights from this poster include:

  • 60% (3 of 5) ORR, including a 40% CR rate observed across brentuximab vedotin refractory patients
  • 64% (7 of 11) ORR, including a 45% CR rate observed across all patients treated

Oral Presentation: Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis (Abstract Number 1125) This oral presentation includes data from patients with myelofibrosis treated with the combination of ruxolitinib, the JAK1/2 inhibitor and TGR-1202.  The combination was well tolerated and efficacious in the twelve patients treated.  The most prevalent adverse events deemed at least possibly related to TGR-1202 included anemia, thrombocytopenia, neutropenia, AST/ALT elevation and amylase/lipase elevation and diarrhea, all of which were notably Grade 1/2 with the exception of Grade 3 amylase/lipase elevation seen in 2 patients (16.7%), and Grade 3 diarrhea seen in 1 patient (8.3%). Presentation highlights included:

  • The patient population enrolled was advanced, with the majority having 2 or more prior mutations at baseline;
  • Per protocol, all enrolled patients were on a stable dose of ruxolitinib monotherapy with best response to ruxolitinib monotherapy achieved prior to enrollment;
  • Following the addition of TGR-1202, 11/12 patients experienced improvement in hemoglobin, many with a concomitant reduction in platelet counts indicating clinical benefit beyond ruxolitinib monotherapy; and
  • 83% of study participants experienced clinical benefit (hematologic improvement, reduced spleen size and/or improvement in symptoms) including one patient who achieved a CR and continues on study, now out 72 weeks

PRESENTATION DETAILS: Copies of the above referenced presentations are available on the Company’s website at www.tgtherapeutics.com , located on the Publications page.

TG THERAPEUTICS INVESTOR & ANALYST EVENT: TG Therapeutics held an investor and analyst reception yesterday, at the Marriott Gaslamp, in San Diego, California.  The audio file and slide presentation are available for review on the Events page, located within the Investors & Media section of the Company’s website at www.tgtherapeutics.com .

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete preclinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies; the risk that early preclinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET inhibitor program, and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303, will not prove to be a safe and efficacious backbone for triple and quad combination therapies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior preclinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G

CONTACT: Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 124

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 51

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 87

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 79

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 34

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 34

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 38

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading

Top 5 Most Recently Viewed Articles

What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 219

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
Saab Expands Military Partnerships with New Colombian Contract

Updated Category News Views 381

Saab's New Military Contract with Colombia In a significant development for both Saab and the Colombian government, the defense company has successfully secured a contract to supply 17 Gripen E/F fighter aircraft. This milestone order, valued at approximately EUR 3.1 billion, is set to bolster Colombia's air defense capabilities over the coming years. Details of the...

Continue Reading
Senske Family of Companies Strengthens Canadian Services with Acquisitions

Updated Category News Views 187

Senske Family of Companies Strengthens Canadian Services with Acquisitions Senske Family of Companies (SFC) is thrilled to announce its latest expansion by acquiring two notable Nutri-Lawn franchise operations, enhancing its presence and service capabilities. Details of the Acquisitions The newly acquired franchises, Nutri-Lawn Mississauga and Nutri-Lawn Fredericton,...

Continue Reading
Understanding Sunstone Hotel Investors' 2024 Dividend Tax Breakdown

Updated Category News Views 171

Tax Treatment of 2024 Dividends by Sunstone Hotel Investors Sunstone Hotel Investors, Inc. (NYSE: SHO) has provided important insights regarding the tax implications for its 2024 dividend distributions. This announcement is pivotal for shareholders who need to understand the tax treatment applicable to their dividends, particularly as it relates to their income tax...

Continue Reading
Strategizing with BABA: A Comprehensive Butterfly Trade Guide

Updated Category News Views 179

Navigating the Financial Waters with a Double Butterfly Trade In today's complex economic landscape, characterized by mixed signals, investors need to stay agile and informed. While initial public offerings (IPOs) have seen a decline, private equity investment is on the rise. Housing trends are juxtaposed, with new housing starts dropping yet home sales increasing. In the...

Continue Reading